Steele Chad, Shellito Judd E, Kolls Jay K
Department of Pediatrics, Division of Pulmonology Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Med Mycol. 2005 Feb;43(1):1-19. doi: 10.1080/13693780400015360.
Species of the genus Pneumocystis exist as opportunistic fungal pathogens and are associated with severe pneumonia and pulmonary complications in immunocompromised individuals. Although prophylactic therapy for Pneumocystis has significantly decreased the overall incidence of infection, more than 80% of cases in current patient populations are considered breakthrough cases. In the HIV-infected population, in the years following the initiation of highly active antiretroviral therapy (HAART), significant reductions in the incidence of Pneumocystis infection were observed, although trends over the last several years suggest that the incidence of Pneumocystis has plateaued rather than decreased. Furthermore, with the more prominent usage of immunosuppressive therapies, the frequency of Pneumocystis infection in the HIV-negative population, such as those with hematologic malignancies and those who have undergone transplantation, has risen significantly. Investigating host defense mechanisms against P. carinii has historically been problematic due to the difficulty in achieving continuous in vitro propagation of proliferating Pneumocytis organisms. Nevertheless, clinical and experimental studies have documented that host defense against Pneumocystis involves a concerted effort between innate, cell-mediated (T lymphocyte) and humoral (B lymphocyte) responses. However, the pulmonary environment is a tissue site where heightened inflammatory responses can often lead to inflammation-mediated injury, thereby contributing to the pathogenesis of Pneumocystis infection. Accordingly, clearance of Pneumocystis from the pulmonary environment is dependent on a delicate equilibrium between the inflammatory response and immune-mediated clearance of the organism. Furthermore, innate and adaptive responses against Pneumocystis are strikingly similar to those against other medically-important fungi, thus providing additional evidence that Pneumocystis exists as a fungal organism.
肺孢子菌属的物种作为机会性真菌病原体存在,并与免疫功能低下个体的严重肺炎和肺部并发症相关。尽管针对肺孢子菌的预防性治疗已显著降低了感染的总体发生率,但当前患者群体中超过80%的病例被认为是突破性病例。在感染HIV的人群中,在开始高效抗逆转录病毒治疗(HAART)后的几年里,观察到肺孢子菌感染的发生率显著降低,尽管过去几年的趋势表明肺孢子菌的发生率已趋于平稳而非下降。此外,随着免疫抑制疗法的更广泛使用,HIV阴性人群(如血液系统恶性肿瘤患者和接受移植者)中肺孢子菌感染的频率显著上升。由于难以实现增殖性肺孢子菌生物体的连续体外繁殖,历史上对宿主针对卡氏肺孢子菌的防御机制进行研究一直存在问题。然而,临床和实验研究已证明,宿主针对肺孢子菌的防御涉及先天、细胞介导(T淋巴细胞)和体液(B淋巴细胞)反应之间的协同努力。然而,肺部环境是一个组织部位,在该部位炎症反应增强往往会导致炎症介导的损伤,从而促进肺孢子菌感染的发病机制。因此,从肺部环境中清除肺孢子菌取决于炎症反应与机体免疫介导清除之间的微妙平衡。此外,针对肺孢子菌的先天和适应性反应与针对其他医学上重要真菌的反应惊人地相似,从而提供了额外证据表明肺孢子菌作为一种真菌生物体存在。